Aptevo Therapeutics (APVO) News Today $1.12 -0.13 (-10.40%) Closing price 04:00 PM EasternExtended Trading$1.08 -0.04 (-3.13%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Aptevo reports two additional AML patients achieve remission in RAINIER trialMarch 21, 2025 | markets.businessinsider.comAptevo Therapeutics advances cancer antibody APVO603 in preclinical phaseMarch 21, 2025 | uk.investing.comAptevo Therapeutics provides overview of APVO603 targeting 4-1BB, OX40March 21, 2025 | markets.businessinsider.comAptevo Therapeutics: RAINIER Trial Data Update: Two Additional AML Patients Achieve Remission Within 30 Days of TreatmentMarch 20, 2025 | finanznachrichten.deAptevo Therapeutics: Aptevo Highlights APVO603: A Novel Bispecific Antibody Targeting 4-1BB and OX40 for Enhanced Solid Tumor ImmunotherapyMarch 18, 2025 | finanznachrichten.deAptevo Therapeutics: Aptevo to Participate in March ConferencesMarch 6, 2025 | finanznachrichten.deRoth MKM Sticks to Its Buy Rating for Aptevo Therapeutics (APVO)February 18, 2025 | markets.businessinsider.comAptevo Therapeutics Interview to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVFebruary 16, 2025 | finanznachrichten.deAptevo Therapeutics reports FY24 EPS ($87.38) vs. ($2,316.83) last yearFebruary 14, 2025 | markets.businessinsider.comAptevo Therapeutics files $100M mixed securities shelfFebruary 14, 2025 | markets.businessinsider.comAPVO stock plunges to 52-week low at $3.62 amid steep annual declineFebruary 13, 2025 | msn.comAptevo Therapeutics Stock Draws Retail Attention After Leukemia Trial Data: Retail Extremely BullishDecember 13, 2024 | msn.comAptevo Therapeutics trading halted, volatility trading pauseDecember 13, 2024 | markets.businessinsider.comAptevo Therapeutics trading resumesDecember 12, 2024 | markets.businessinsider.comAptevo Therapeutics announces additional details about APVO442December 5, 2024 | markets.businessinsider.comAptevo Therapeutics announces additional details about APVO442December 5, 2024 | markets.businessinsider.comAptevo Therapeutics: Proving the Concept: Aptevo Technology, Pipeline, to Exemplify the Speed and Power of Modular Biotherapeutics at PresentationNovember 26, 2024 | finanznachrichten.deAptevo Therapeutics highlights potential of portfolio in cancer immunotherapyNovember 23, 2024 | markets.businessinsider.comAptevo Therapeutics: First-in-Class Bispecific Antibody, ALG.APV-527, Meets Important Trial Endpoints in Phase 1 Solid Tumor TrialNovember 12, 2024 | finanznachrichten.deAptevo Therapeutics (NASDAQ:APVO) Stock Quotes, Forecast and News SummaryOctober 5, 2024 | benzinga.comAptevo Therapeutics (NASDAQ:APVO) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comClinuvel Pharmaceuticals Limited (UR9.F) Stock Price, News, Quote & History - Yahoo FinanceSeptember 24, 2024 | finance.yahoo.comAptevo Therapeutics: Phase 1b/2 "RAINIER" Frontline Acute Myeloid Leukemia Trial InitiatedAugust 13, 2024 | finanznachrichten.deBiotech Seeing Significant Buying Pressure Before The Opening BellJuly 19, 2024 | theglobeandmail.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q1 2024May 8, 2024 | investorplace.comWhy Aspen Aerogels Shares Are Trading Higher By 26%; Here Are 20 Stocks Moving PremarketMay 2, 2024 | msn.comWhy Aptevo Therapeutics Stock Is CrateringApril 11, 2024 | msn.comWhy Is Aptevo Therapeutics (APVO) Stock Down 56% Today?April 11, 2024 | investorplace.comAptevo Therapeutics Up 20% on Positive Interim Data for Tumor DrugMarch 7, 2024 | marketwatch.comAlligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4March 7, 2024 | finance.yahoo.comTrading was temporarily halted for "APVO" at 11:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 10:03 AM with a stated reason of "LULD pause." Trading set to resume at 11:03 AM. March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 11:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 10:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comTrading was temporarily halted for "APVO" at 09:03 AM with a stated reason of "LULD pause."March 7, 2024 | marketbeat.comAptevo Therapeutics Inc (AP8N.BE)March 6, 2024 | ca.finance.yahoo.comAptevo Therapeutics enacts reverse stock split to meet Nasdaq requirementsMarch 6, 2024 | investing.comTrading was temporarily halted for "APVO" at 07:03 PM with a stated reason of "News pending."March 6, 2024 | marketbeat.comAPVO Stock Earnings: Aptevo Therapeutics Beats EPS for Q4 2023March 5, 2024 | investorplace.comAptevo Therapeutics Inc (AP8N.DU)March 5, 2024 | finance.yahoo.comAptevo Therapeutics down 13%, will effect 1-for-44 reverse stock splitMarch 4, 2024 | msn.comPD-1 and PD-L1 Inhibitors Competitive Landscape Report 2024: Clinical Assessment of Over 200 Drugs Being Developed by More than 180 CompaniesMarch 1, 2024 | uk.finance.yahoo.comAptevo Therapeutics Inc (APVO)February 9, 2024 | investing.comAptevo Therapeutics Stockholders Approve Reverse SplitFebruary 7, 2024 | msn.comAptevo Therapeutics Inc. (APVO)January 24, 2024 | finance.yahoo.comAptevo Therapeutics files to sell up to 32.03M shares of common stock for holdersNovember 22, 2023 | msn.comAptevo Therapeutics GAAP EPS of -$0.50November 14, 2023 | msn.comAptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business UpdateNovember 14, 2023 | finance.yahoo.comAptevo Therapeutics: Aptevo to Present at Bio-Europe ConferenceNovember 1, 2023 | finanznachrichten.deAptevo to Present at Bio-Europe ConferenceNovember 1, 2023 | finance.yahoo.com Remove Ads Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address APVO Media Mentions By Week APVO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. APVO News Sentiment▼0.360.78▲Average Medical News Sentiment APVO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. APVO Articles This Week▼20▲APVO Articles Average Week Remove Ads Get Aptevo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies HCWB News IPA News CTXR News ATHA News BMRA News NERV News ORGS News FLGC News CING News GOVX News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:APVO) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump’s Treasure Map [Pic inside]We were shown this map by former Presidential Advisor, Jim Rickards, one of the most politically connected men...Paradigm Press | SponsoredDo this Before Elon's Reveal on April 23rdElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredMost gold “analysts” aren’t really gold analysts… [watch out]People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aptevo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
